Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intas Pharmaceuticals Ltd.

www.intaspharma.com

Latest From Intas Pharmaceuticals Ltd.

Is Dexamethasone The Next Hydroxychloroquine For India?

While the jury is still out on dexamethasone being the new hero in the fight against COVID-19 after the hype around hydroxychloroquine has died down, Indian pharma is watching developments closely. Gains of companies like Zydus Cadila, Wockhardt, Cadila and Cipla in the domestic market will be constrained by price caps while any increase in exports will depend on emergency use authorizations.

Coronavirus COVID-19 India

Indian Industry Gets HCQ, Paracetamol Exports Rolling

Indian manufacturers hope increased production of hydroxychloroquine and paracetamol, along with emergence of reliable COVID-19 therapies, will lead to export restrictions on these two medicines being removed soon. Meanwhile, they are fulfilling orders routed through the government.

Policy Coronavirus COVID-19

India’s Paracetamol Exports Hit By Coronavirus Fallout

India permits medicines placed on a restricted list to be exported from SEZs and under advance licenses, but paracetamol exporters hope for more easing as restrictions begin to hurt. Meanwhile, the government asks industry to ensure four months of stock as it balances medicines security with economic interest.

Policy & Regulation Coronavirus COVID-19

Mylan's Aflibercept Biosimilar Gets Green Light For Trials In India

Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.

Biosimilars Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Intas Pharmaceuticals Ltd.
  • Senior Management
  • Contact Info
  • Intas Pharmaceuticals Ltd.
    Phone: (91) 79 3983 7000
    Corporate House, Near Sola Bridge
    S. G. Highway
    Ahmedabad, 380054
    India
UsernamePublicRestriction

Register